Development of new active pharmaceutical ingredients (APIs) is lengthy and cost-intensive, thus avoiding any potential risk that may limit the product’s success is of utmost importance. Today, many APIs are not being commercialized as they are poorly water soluble and, as a result, exhibit too low bioavailability.
The Developability Classification System was developed to assist formulation scientists by introducing two new compound categories: Dissolution rate limited (DCS IIa) and solubility limited (DCS IIb). Depending on where your API lies, there are various strategies to optimize formulation of poorly soluble molecules - From particle size reduction, to solid state modification, to API processing techniques like salt and cocrystal formation.
An on-demand version of this webinar will be available after the live event using the same link. Register now and access the webinar at your convenience.